|
GSK PLC on Monday reported encouraging trial data for its cancer treatment Jemperli, also known as dostarlimab. The London-based pharmaceutical firm said the drug was linked to ‘sustained clinical complete responses’ in patients with a type of bowel cancer. Specifically, the data related to stage two/three mismatch repair deficient/microsatellite instability-high locally advanced rectal cancer. The trial met its primary objective of a meaningful and sustained clinical response rate after one year. ‘These results support the potential for dostarlimab, if approved, to become the first immunotherapy capable of eliminating or delaying the need for chemotherapy, radiation and surgery for some patients in this population,’ GSK noted. Hesham Abdullah, the company’s senior vice president and global head of Oncology, Research & Development, commented: ‘The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data demonstrate that some patients may be able to avoid those interventions while remaining free of detectable signs of cancer.’ Dostarlimab already has breakthrough therapy and fast-track status from the US Food & Drug Administratiob. Filings with regulators in other territories are planned in future. The drug was discovered by San Diego, California-based AnaptysBio Inc and licensed to Tesaro Inc under an agreement signed in 2014. GSK acquired Waltham, Massachusetts-based Tesaro in 2019, making it responsible for the drug’s development and commercialisation. GSK shares rose 0.3% to 1,967.50 pence on Monday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
